- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04743908
Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US (C3)
March 12, 2024 updated by: University of Chicago
Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US (C3)
This C3 project, Community network-driven COVID-19 testing of vulnerable populations in the Central US, will implement and evaluate a COVID-19 testing and vaccination approach that combines an evidence-based Social Network Testing Strategy (SNS) with community developed COVID-19 public health messages (SNS+).
C3 will engage two disenfranchised populations across rural and urban sites in states across the Central US (Texas (TX), Louisiana (LA), Arkansas (AR), Indiana (IN), Illinois (IL)).
C3 leverages NIDA's Justice Community Opioid Innovation Network (JCOIN), the PIs' extensive community located COVID-19 testing programs, and a network of established community partnerships.
The collaborative community-academic partnerships, research and engagement infrastructure, and team's leadership across JCOIN will ensure that C3 can rapidly recruit, enroll and test most disenfranchised community members, (n=2400) and through this process, accelerate any forthcoming COVID-19 public health prevention interventions.
C3 focuses on two communities most impacted by COVID-19: 1) Criminal justice involved (CJI) - non-incarcerated people with previous history of arrest/jail/prison, probation/parole, drug-court attendance, witnessed or experienced a negative interaction with police or law enforcement; and 2) Low-income Latinx - community members at 250% or below Federal Poverty Level.
Both of these diverse populations, and the overlap between them, have some of the highest rates of COVID-19 infection and death in the United States.
Messaging that affirms individual agency and corrects misinformation, combined with accessible and acceptable testing, is required to accelerate COVID-19 prevention for these populations.Using a two-arm randomized controlled trial design, participants will be enrolled into the Social Network testing Strategy (SNS) arm (involves social networking referrals only) or the Social Network testing Strategy with COVID-19 prevention messages (SNS+) messaging arm.
The latter includes affirmation/misinformation correction messaging (discussion tools and coaching).
SNS and SNS+messaging arms will both include an initial group of index study participants who will refer their network members into the study and the process will repeat itself one more time for a total of 3 waves.
Indexes will refer network members (1st degree) and then those network members will refer one more round (2nd degree).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1328
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mainza L Durrell, DrPH
- Phone Number: 7737027589
- Email: mdurrell@medicine.bsd.uchicago.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion criteria:
Index community members will be:
- 18 years or older (15-28 years old at University of Indiana site);
- spend majority of their time in the metropolitan area or county where recruited;
- have access to a phone for 21-day follow-up call; and
- primary communication in English or Spanish (based on site; Spanish language for Howard Brown/Project Vida and UTSW) AND at least one of the following: (i) ever had CJI (operationalized as any jail, prison, arrest, parole (completed), probation, drug court); (ii) ever had negative interaction with police or law enforcement that did not lead to an arrest or jail/prison time (operationalized as ever stopped, searched, physically or verbally abused, or had another negative interaction with police or law enforcement); (iii) ever witnessed a negative interaction with police or law enforcement (iv) lower-income Latinx (operationalized as at or below 250% of FPL) (Not applicable for University of Indiana).
Social network referrals will be:
- linked to the index as a "friend, family, coworker or someone you spend time with on a regular basis";
- visit within two weeks of index visit;
- 18 years or older;
- spend the majority of their time in the metropolitan area or county where recruited;
- have access to a phone for 21-day follow-up call; and
- primary communication in English or Spanish.
Exclusion Criteria:
- inability to provide informed consent; and
- active COVID-19 symptoms per the Centers for Disease Control and Prevention (CDC). Participants with COVID-19 symptoms will be referred for free testing at existing partners for each of the study sites.
- currently on parole
- for the University of Indiana site, currently in foster care, on house arrest, on probation, detained at a federal facility or had a police encounter during which the officer(s) either asked for some form of identification and/or issued a traffic ticket, but did not have other CJI involvement.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Social Network Strategy (SNS Condition)
Study staff will describe the Social Network Strategy, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts.
Study staff will specifically discuss network members of interest: "friend, family, coworker or someone you spend time with on a regular basis".
Walkthrough and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared.
|
|
Experimental: Social Network Strategy + Messaging
Study staff will describe the Social Network Strategy, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts.
Study staff will specifically discuss network members of interest: "friend, family, coworker or someone you spend time with on a regular basis".
Walk through and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared.
Finally, community developed COVID-19 public health messages will be shared in the participant's preferred language.
|
Contextually adapted and theory-driven messages - misinformation correction and self-affirmation - to increase awareness, self-efficacy and community engagement in our adapted Social Network testing Strategy (SNS).
SNS is an evidence-based testing intervention that has been widely used in multiple settings with marginalized individuals (ie substance-users) who facilitate the recruitment of their social contacts into testing services.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total number of tests among network members referred for COVID testing (network tested).
Time Frame: 12 months
|
Network tested is measured at the participant level by the number of network members that are tested through the SNS.
|
12 months
|
Total number of vaccinations among study participants given COVID vaccine information (number vaccinated)
Time Frame: 12 months
|
Number vaccinated is measured at the participant level by the number of study participants that are vaccinated through the SNS.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: John Schneider, MD, University of Chicago
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 29, 2021
Primary Completion (Actual)
December 31, 2022
Study Completion (Actual)
December 31, 2022
Study Registration Dates
First Submitted
February 5, 2021
First Submitted That Met QC Criteria
February 5, 2021
First Posted (Actual)
February 8, 2021
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 12, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB20-1494
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Social Network Strategy + COVID-19 messaging
-
Chulalongkorn UniversityCompletedMen Who Have Sex With Men | Social Network Strategy | HIV Self TestingThailand
-
PATHUNITAID; Zoram Medical College (ZMC); Pacchunga University College; Association... and other collaboratorsNot yet recruiting
-
University of ChileNot yet recruitingCovid19 | Death | Infectious Disease | SARS-CoV InfectionChile
-
Jean LiuCompleted
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Georgia... and other collaboratorsRecruiting
-
Stanford UniversityUniversity of California, San Francisco; Wuqu' Kawoq, Maya Health AllianceCompletedVaccination RefusalGuatemala
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingPhysical ConditioningUnited States
-
Mayo ClinicCompletedCoronavirus Disease (COVID-19)United States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingImproving Blood Pressure ControlUnited States
-
University of California, San DiegoSan Ysidro Health CenterRecruitingCOVID-19 | COVID-19 PandemicUnited States